Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?

Abstract excerpt

Significant advances in treatment and monitoring for patients with chronic myeloid leukemia have occurred over the last decade. With the introduction of the tyrosine kinase inhibitor imatinib, long-term outcomes have improved and new challenges, such as resistance, including mutations, have emerged. Research efforts into mutational analysis have intensified, with emphasis on the potential of using this technique...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzamides
• Share to Dasatinib
• Share to Imatinib Mesylate